Physician profile
Jeffrey E Taxman
NPI 1114066610
$533.12
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $61.41 · 2022: $15.58.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $264.63 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.16 | 2019 | |
| Alkermes, INC. | $41.38 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $39.87 | 2019-2020 | |
| Lundbeck LLC | $35.30 | 2019 | |
| Allergan, INC. | $25.16 | 2019 | |
| Shire North American Group INC | $24.12 | 2019 | |
| Bausch Health US, LLC | $22.02 | 2020 | |
| Adlon Therapeutics L.P. | $16.90 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.58 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Taxman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.